The Hematologist

banner image

Hematology... Literally and Seriously

Dr. Jason Gotlib provides his perspective on 2016's groundbreaking progress in hematology and his thoughts on navigating the new Administration.

Read more
banner image

BTK Inhibition Saunters to the Front of the Line in CLL

Dr. Moss covers updates in the management of the most common subtype of leukemia, focusing on the value of BTK inhibition.

Read more
banner image

Podcast: Year's Best in SCD

Drs. Jason Gotlib and Alexis Thompson discuss the highlights of 2016 in sickle cell disease including related studies and ASH SCD initiatives.

Play here
Current Issue Static Feature

Current Issue

January/February 2017              
Volume 14, Issue 1

Read current issue

President's Column

Presidents Column - Kenneth AndersonKraft Family Professor of Medicine, Harvard Medical School; Director Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center Dana-Farber Cancer Institute, Boston, MA
Motivation for Education
January 1, 2017

Dr. Kenneth Anderson ushers in 2017 spotlighting the Society's education mission.

View all president's column articles

  • DEA Eliminates Grace Period for Registration Renewal
    December 21, 2016

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model
    December 20, 2016

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

  • NHLBI Small Business Innovation Research Funding Opportunity Fosters Production of Blood Cells From Stem Cells
    November 23, 2016

    ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.

  • 2016 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait
    November 17, 2016

    The American Society of Hematology (ASH) is committed to addressing the burden of sickle cell disease (SCD) and is undertaking a multifaceted initiative to improve outcomes for individuals with the disease, both in the United States and globally.

View all Policy News